About one year ago, patients received a single injection of Cx601. Half of the patients were healed after 24 weeks. One year later, 1 in 2 (54%) patients still experiences the positive effect of the drug. This is very good news for TiGenix, because if diseases can be cured with a single injection, the probability increases that the product will be reimbursed by the health insurance. Previous studies already showed that the treatment has a favorable safety profile. Moreover, these results equip TiGenix with extra leverage to go to investors and pharma companies. The biotech company is looking for a pharmaceutical company to fund the last stage of the clinical trial in the US and wants to make an IPO on NASDAQ.
BioVox
With a local focus and global reach, BioVox shares insights into the Belgian life sciences ecosystem with an ever-growing global community. BioVox is a non-profit project: we are able to provide our community with free, quality content because of the generous support of Turnstone Communications and its clients. Our articles bring you hidden opportunities and exclusive insights into the latest research and industry trends!
All posts